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Ablynx Makes Nanobodies from Llama BodiesAntibodies, the sentinels of the im-
mune system, are ‘‘Y’’ shaped, glob-
ular proteins with sites that bind
to specific antigens. Antibodies are
produced by B lymphocytes in re-
sponse to stimulation by an antigen.
Antibodies are versatile; they can
bind to proteins, nucleic acids, car-
bohydrates, and lipids, making them
eminently useful in the development
of diagnostics and drugs for the
treatment of autoimmune, inflamma-
tory, and infectious diseases, as well
as cancers.
Antibodies comprise two heavy
and two light protein chains studded
by sugars. An antibody’s ability to
bind specifically to an antigen is dic-
tated by its variable antigen binding
region, which is comprised of both
a heavy (VH) and light (VL) protein
chain. An antibody binds noncova-
lently, like a lock and key, to a corre-
sponding antigen binding site, called
an epitope. B cells produce anti-
bodies that recognize different epi-
topes on an antigen (for example,
different domains of a protein). Anti-
bodies derived from a population of
B cells are polyclonal.
Monoclonal antibodies, or mAbs,
are produced by immortalized B
cells derived from a single parent
cell. The team of Ce´sar Milstein,
Georges Ko¨hler, and Niels Kaj Jerne
developed the techniques to create
mAbs in 1975 and earned the Nobel
Prize in Physiology or Medicine in
1984 for their accomplishment. Re-
searchers and clinicians were ex-
cited about mAbs for therapeutics
because they are so specific; they
can be tailored to recognize and bind
predictably to a particular epitope
on an antigen.
The enthusiasm over therapeutics
waned because mAbs were largely
produced in mice, and the mouse
proteins can cause immunogenic re-
actions in humans. In the late 1980s,
a team at the Medical Research
Council Laboratory for Molecular
Biology (MRC-LMB), led by Sir
Gregory Winter, used recombinant
DNA approaches to ‘‘humanize’’ the
mouse-produced antibodies; i.e.,grafting elements of rodent mAbs
onto human antibody sequences as
well as developing synthetic anti-
bodies that could be expressed
in bacteria and phage. (Another
method of humanizing antibodies





bodies’’ by Ablynx, which
are a tenth of the size of
a conventional antibody.
Therapeutic antibodies are now a
reality. ‘‘If we take monoclonal anti-
bodies, they have been very suc-
cessful,’’ said Edwin Moses, CEO of
Ablynx. ‘‘There are roughly 18 anti-
body-based products already on the
market. There are predictions that
potential sales in the antibody area
will be $10 billion in 2008.’’ Accord-
ing to Moses, the high selectivity
and high affinity of mAbs to their
targets reduces the chances of side
effects.
But the large size and complex
structures of antibody drugs ex-
cludes some attractive therapeutic
targets, such as most enzyme active
sites and deep receptor clefts; bind-
ing to those regions is the realm
of small molecule drugs. They are
also costly to produce in mamma-
lian cells. Moses noted that Wyeth’s
antibody-derived drug Enbrel cost
$1000 a gram to produce (according
to 2001 figures). Additionally, mAbs
must be injected and don’t store
well.
Thinking Small
Ablynx (www.ablynx.com), an 81
person Belgian company, could
solve both problems that have be-
deviled antibody engineers by pro-
ducing fully functional antibodies
with a compact structure. Ablynx
capitalizes on an evolutionary pecu-liarity of camels and their cousins,
the llamas (and certain species of
sharks). Members of the camelid
family are known for their ability
to carry heavy loads and their pro-
pensity to curse and spit. They can
also produce fully functional minia-
ture antibodies, dubbed ‘‘nano-
bodies’’ by Ablynx, which are a tenth
of the size of a conventional anti-
body.
Nanobodies comprise the antigen
binding fragment of the heavy chain
of an antibody. They are compara-
tively small molecules, between
12,000 to 15,000 Da in molecular
weight. Nanobodies can be en-
coded by a single gene and pro-
duced in bacteria and yeast for a fifth
of the cost of a mAb. ‘‘The other big
advantage nanobodies have over
monoclonal antibodies is . their
stability.’’ said Moses. ‘‘They are
very resistant to treatment with heat
and acids.’’
Antibody engineers are also at-
tempting to solve the size problem
by producing fragmentary anti-
bodies called Fab fragments that are
made up of a light chain and part of
a heavy chain, or by developing
single chain variable region frag-
ments (sFv), which are heavy and
light variable regions knit together
by a short chain of about 15 amino
acids. Moses commented that it is
challenging to artificially engineer
protein scaffolds and fragments to
get the specificity and affinity of
naturally derived antibodies. ‘‘De-
veloping artificial antibodies is diffi-
cult. They tend not to be stable.
They tend to aggregate.’’
‘‘The other difficulty is that each
fragment tends to have a different
half life in vivo,’’ said Ian Wilson, pro-
fessor, Department of Molecular
Biology and the Skaggs Institute
for Chemical Biology at The Scripps
Research Institute. ‘‘In general, the
smaller the fragment, the shorter the
half-life.’’ According to Wilson, other
drawbacks to antibody fragments
can be the lack of Fc regions; hence,
some of the usual clearance and ef-
fector mechanisms are not utilized.
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Ablynx maintains a revolving herd of
about 20 llamas, which it buys from
pet dealers and later resells. Llamas
can be immunized a number of
times. Why llamas? While llamas
are easier to handle than camels,
‘‘.llamas spit as well.’’ said Moses.
‘‘There are also differences in anti-
bodies produced by llamas than by
camels.’’ According to Moses, after
immunizing the llamas with a target
protein, it takes about 6–12 weeks
to isolate the first nanobodies
against the target. Then to optimize,
humanize, and format the nano-
bodies takes another 6–12 months.
Ablynx can configure linked nano-
bodies to target two different tar-
gets/epitopes on an antigen.
To avoid the immunogenic reac-
tions created by using natural prod-
ucts, Ablynx does not derive its anti-
bodies directly from the llama. They
isolate the nanobodies and then de-
termine their amino acid sequences.
From that information, the company
can predict the gene sequence, en-
abling them to produce them artifi-
cially. So far, Ablynx’s antibodies
have been shown effective against
100 different targets in vitro.
‘‘Dromedaires’’ to the Rescue
The discovery of the miniature camel
antibody ‘‘was a pure coincidence,’’
said Dr. Serge Muyldermans, one of
the original researchers and a co-
founder of Ablynx. A group of biol-
ogy students at the Free University
of Belgium in 1990 were asked to
draw blood from each other but
refused for fear of HIV. They also re-
fused to kill a mouse to obtain blood.
‘‘So we gave them blood from a
dromedaire that we had in the lab,
as there was another group working
on parasitic diseases,’’ Muylder-
mans recalled.
The students purified the camel
blood serum and noticed curious
antibodies. ‘‘We were trying to clone
antibodies from hybridomas (artifi-
cial cells created by fusing a tumor
cell with a B-lymphocyte) and to
express [them] in bacteria,’’ said
Muyldermans. ‘‘There was always
something going wrong. We noticed
in camels [that] we didn’t have
antibodies with the light chain. That
immediately solved part of the
problem.’’
While the general concept of
nanobodies was patented in 1992,and the discovery was published in
Nature in 1993, it wasn’t until 2001
that Ablynx was founded with the
aid of the university tech transfer
office. Last year alone, Ablynx
raised $50 million (making the total
funds the company has raised from
investors $87 million). Ablynx col-
laborates with pharma companies
including Wyeth Pharmaceuticals,
Novartis, Centocor, Kirin Breweries,
and P&G Pharmaceuticals.
Sending Nanobodies into the Fray
Ablynx is targeting some areas that
are currently being treated by small
molecule drugs as well as those
covered by other antibody applica-
tions. ‘‘The most obvious thing for
us to do is to look at targets where
antibodies have already been shown
to work,’’ said Moses. ‘‘If nothing
else, we will have the cost-of-goods
advantage, though to date we have
also seen improved efficacy and
safety profiles.’’
Ablynx’s most advanced program
is in thrombosis. Their reagent has
been tested in animal models, and
they expect to file an IND in Europe
to begin volunteer clinical trials in the
first quarter of 2007. Ablynx has a
preclinical TNFa-blocker nanobody,
licensed to Wyeth for rheumatoid
arthritis. Wyeth currently markets
the multi-billion dollar drug Enbrel
for this indication.
U.K.-based Domantis, Ltd., (www.
domantis.com) is probably Ablynx’s
closest rival. Sir Gregory Winter
cofounded Domantis, Ltd., in 2000
with Dr Ian Tomlinson to commer-
cialize the domain antibodies that
they developed. Domain antibodies
are the smallest functional binding
units ofantibodies,corresponding to
either heavy or light protein chains
of human antibodies. Domantis says
its human dAbs are stable for
therapies in inflammatory diseases,
cancers, and autoimmune diseases.
Domantis’ collaborators include Ab-
bott Laboratories, and they raised
$83 million prior to being purchased
in early December by Glaxo-
SmithKline for $454 million in cash.
Other players in the antibody field
are looking beyond the basic anti-
body structure to develop new
reagents for specific recognition.
These approaches typically involve
replacing the heavy and light
chain scaffolds with other biology-
inspired structures. Pieris (www.pieris-ag.com) in Germany is using
lipocalins as a scaffold (named
anticalins). Affibody (www.affibody.
com) in Sweden is using the protein
A domain as a scaffold to focus
on cancer diagnostics. Molecular
Partners, AG, (Switzerland) (www.
molecularpartners.com) uses a syn-
thetic ankyrin as a scaffold. Their
DARPins (designed ankyrin repeat
proteins) bind to targets like anti-
bodies but have better stability and
expression, according to the com-
pany. Molecular Partners is now
evaluating repeat proteins for the
tumor market.
Worth the Trek
Ablynx is still an early stage com-
pany, but its venture capitalists tout
its strong IP position and promising
animal data. ‘‘It is not very often
you come across what is a poten-
tially a new class of therapeutics,’’
said, Katya Smirnyagina, Ph.D., ven-
ture partner at San Francisco-based
Alta Partners. ‘‘The proof of concept
is of course, going to man.’’
It is an ambitious venture, but a
reliable team of llamas can carry
a company far.
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